Design and comparative in-vitro and in-vivo evaluation of starch-acrylate graft copolymer based salbutamol sulphate sustained release tablets  by Kumar, Pankaj et al.
w.sciencedirect.com
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 3 9e2 4 6HOSTED BY Available online at wwScienceDirect
journal homepage: ht tp: / /ees.e lsevier .com/ajps/defaul t .aspOriginal Research PaperDesign and comparative in-vitro and in-vivo
evaluation of starch-acrylate graft copolymer based
salbutamol sulphate sustained release tabletsPankaj Kumar a,*, Ashok Laxmanrao Ganure b, Bharat Bhushan Subudhi a,
Shubhanjali Shukla c, Pooja Upadhyay d
a School of Pharmaceutical Sciences, Siksha O Anusandhan University, Khandagiri Square, Bhubaneswar,
Orissa 751030, India
b Sahyadri College of Pharmacy, Sangola, Solapur, M.S. 413307, India
c Department of Pharmaceutics, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India
d Department of Advanced Pharmaceutical Science, Manipal University, Karnataka 576104, Indiaa r t i c l e i n f o
Article history:
Received 6 May 2014
Received in revised form
9 November 2014
Accepted 4 December 2014
Available online 22 December 2014
Keywords:
Salbutamol sulphate
Methyl methacrylate
Graft copolymers
Acetylated starch
Korsmeyer's model
In vitro and in vivo* Corresponding author. School of Pharmaceu
751030, India. Tel.: þ91 9221715720.
E-mail address: pankajnil@yahoo.com (P. Ku
Peer review under responsibility of Shenyan
http://dx.doi.org/10.1016/j.ajps.2014.12.003
1818-0876/© 2014 Shenyang Pharmaceutical
CC BY-NC-ND license (http://creativecommoa b s t r a c t
The present work deals with the development of controlled release tablets of salbutamol
sulphate (SS) using graft copolymers of methyl methacrylate (St-g-PMMA and Ast-g-PMMA)
on starch and acetylated starch. Formulations were evaluated for physical characteristics
like hardness, friability, drug release, drug content and weight variations, which fulfilled all
the official requirements of tablet dosage form. The release rates from formulated matrix
tablets were studied at SGF (pH 1.2) followed by SIF (pH 6.8). Drug release from the graft
copolymer based tablets was found to be sustained upto the 14 h with >75% drug release.
The in-vitro release study showed that the graft copolymer based matrix formulations (F3 &
F4) exhibited highest correlation value (r2) for higuchi kinetic model and Korsmeyer's
model with n values between 0.61 and 0.67 proved that release mechanisms were governed
by both diffusion and erosion mechanism. There was no significant difference in the
pharmacokinetic parameters (tmax, Cmax, AUC, Ke, and t1/2) of the graft copolymers matrices
and HPMC K100M matrix tablets, indicating their comparable sustained release effect. The
potential of graft copolymers to sustain the drug release is well supported by in-vivo
pharmacokinetic studies and their adequate physicochemical properties make them
promising excipients for controlled drug delivery system.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).tical Sciences, Siksha O Anusandhan University, Khandagiri Square, Bhubaneswar, Orissa
mar).
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Table 1 e Composition of salbutamol sulphate controlled
release tablets.
S. No. Ingredients Formulation code
F1 F2 F3 F4 F5
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Controlled release technology has rapidly emerged over the
past few decades as a new interdisciplinary science that offers
novel approaches for delivery of bioactive agents into sys-
temic circulation at a predetermined rate, achievement of
optimum therapeutic responses, prolonged efficacy and
decreased toxicity [1]. Salbutamol Sulphate (SS), a directly
acting sympathomimetic drug, is a good candidate for
controlled release formulations since its short half life (2e4 h)
which necessitates frequent administration to maintain con-
stant therapeutic drug levels, but it is challenging because of
its high water solubility [2]. In recent years, use of natural
polymers such as starch, cellulose, chitosan etc. as carriers in
controlled drug delivery applications has attracted the atten-
tion of investigators because of their inherent biocompati-
bility, biodegradability and biosafety [3e5]. But natural
polymers share some common disadvantages like poor flow
properties, inadequate compression behavior, thermal liabil-
ity and enormous swelling owing to their hydrophilic nature.
Hydrophilicity results in premature release of drug in the
stomach/upper intestine, and therefore they should be pro-
tected while gaining entry into stomach and small intestine.
This can be achieved by the modification of polysaccharides,
such as cross linking, addition of protective coating, or graft-
ing using acrylic monomers [6e8]. Among the currently
available graft copolymers, starch-based graft copolymers has
drawn considerable attention due to their potential value as
directly compressible excipients for controlled release
matrices and methyl methacrylate was chosen for grafting
because of its knownbiocompatibility and non-toxic behavior,
together with its hydrophobicity and ease of polymerization
[9,10]. In terms of controlled release formulations, reservoir
andmatrix type tablets are most commonly used for modified
release formulation. Especially matrix tablets, in which drug
particles are embedded in the matrix core of the retardant
polymeric material, formulated with direct compression
technique, one of the best method to sustain the release rate
effectively over a period of 10 h [11]. The afore mentioned
facts, directed our interest to design oral controlled release
matrix tablets of SS using starch-based graft copolymers as
hydrophobic inert matrix. Evaluation of tablets for various
physical characteristics, in-vitro release study and in-vivo
bioavailability studies in rabbits upon oral administration
were performed. Release kinetics are studied in depth by
fitting dissolution profile in various kinetic models (viz. zero
order, first order, Higuchi, HixoneCrowell and Kors-
meyerePeppasmodels) and in-vitro-in-vivo correlation (IVIVC) is
established by using the WagnereNelson method.
Qty (mg/tablets)
1 Salbutamol sulphate 8 8 8 8 8
2 Maize starch 159 e e e e
3 Acetylated starch (Ast) e 159 e e e
4 St-g-PMMA e e 159 e e
5 Ast-g-PMMA e e e 159 e
6 Hypromellose
(HPMC K 100 M PREMIUM)
e e e e 159
7 Spray dried lactose 30 30 30 30 30
8 Magnesium stearate 3 3 3 3 3
Total weight 200 200 200 200 2002. Materials and methods
2.1. Materials
Maize starch (St) was obtained from Universal Starch Chem
Allied Ltd., (Mumbai India). Solvents of analytical grade were
obtained fromMerck Ltd., Germany. Gift sample of salbutamol
sulphate was received fromMicro Labs Limited Ltd., (Mumbai,India). Sprayed dried lactose and magnesium sulphate were
obtained from Micro Labs Limited Ltd., (Mumbai, India).
Hydroxypropylmethyl cellulose (HPMC K 100) was obtained
from Micro Labs Limited Ltd., (Mumbai, India).
2.2. Method
2.2.1. Synthesis of acetylated starch and graft copolymers
[starch grafted poly (methyl methacrylate) (St-g-PMMA) &
acetylated starch grafted poly (methyl methacrylate)
(Ast-g-PMMA)]
Acetylated starch (Ast) and graft copolymers were prepared in
laboratory, based on information provided in our recent
published research article [12]. Here on starch back bone,
methyl methacrylate was grafted via redox reaction.Wherein,
Ce(IV) ionwas reduced to Ce(III) ion andmade an active site on
starch back bone for grafting of methyl methacrylate.
Synthesized samples were used for further study.
2.2.2. Tabletting
2.2.2.1. Blend preparation. HPMC K100M was chosen for
comparison with graft copolymers for its controlled release
properties. Various combinations were selected and blend
was prepared for salbutamol sulphate using starch/acetylated
starch (Ast)/St-g-PMMA/Ast-g-PMMA/HPMC K100M, spay
dried lactose, andmagnesium stearate. These were physically
blended until a homogenous mixture was obtained (compo-
sition as shown in Table 1). No more additives were included
in order to get intrinsic information of the polymeric material
itself.
2.2.2.2. Angle of repose. Angle of repose was derived for the
powder blend as an indicator for flowability characteristics.
This was determined by a fixed funnel and free standing cone
method [13]. The blend was poured through a funnel that can
be raised vertically until a maximum cone height (h) was
obtained. Radius of the heap (r) wasmeasured and the angle of
repose (q) was calculated by using the formula:
q ¼ tan1 (h/r)
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direct compression method. The homogenous mixtures of
different blends with required flow properties were shifted
through #60 sieve. This was manually fed into the die and
compressed in hydraulic press using an 8 mm flat faced
punch, with the crushing force of 70e80 N. The compressed
tablets were flat and round shaped, with average weight of
200 mg. Physicochemical properties for various parameters
were assessed on 50 tablets.
2.2.3. Evaluation of tablets
2.2.3.1. Physical testing. The physical testing on tablets of
each batch was performed after a relaxation period of at least
24 h. Weight variation test was performed on 20 individually
weighed (Citizen CY204 Analytical Balance, Minnesota, USA)
tablets according to the official method of United State Phar-
macopoeia. The thickness and diameter of ten tablets were
measured individually using vernier caliper (Edutek Instru-
mentation, Ambala, India) and average value of thickness was
calculated. The crushing strength (Newton) of prepared tab-
lets was determined using Monsanto hardness tester (MHT-
20, Campbell Electronics, Mumbai, India). Tablet friability was
calculated as the percentage of weight loss occurred due to
attrition during revolution of plastic chamber in 4 min span at
the rate of 25 rpm, performed on 20 tablets using Roche fria-
bilator (C-FT-20, Pharma Chem Machineries, Mumbai, India).
2.2.3.2. Drug content. Ten tablets were weighed individually
and crushed into a fine powder by mortar and pestle. Crushed
powder was weighed with quantity equivalent to 10 mg of the
drug; this was transferred in five volumetric flasks separately.
Distilled water was poured into each conical flask and these
flasks were further subjected to sonication. Drug was extrac-
ted from 50 ml solution prepared previously using bath soni-
cator, with sonication time of 2 min. The actual drug content
was determined using high performance liquid chromatog-
raphy system of Adept series CECIL CE 4201 with UV/Visible
detector at 277 nm and the drug concentration was deter-
mined using the standard calibration curve, covering the drug
concentration from 5.0 to 50.0 mg/ml.
2.2.4. In vitro and in vivo studies
2.2.4.1. In vitro release studies. In-vitro release study was
carried out using USP dissolution type II apparatus, with
rotation speed of 50 rpm to provide information regarding in-
vitro drug release information. This study was performed in
simulated gastric fluid (0.1N HCl) for 2 h followed by same
volume of simulated intestinal fluid (PBS, pH 6.8) for next 12 h.
The dissolution media (900 ml) was maintained at 37 ± 0.5 C
throughout the study. At predetermined time intervals of 0, 1,
2, 3, 4, 5, 6, 8, 10, 12 and 14 h, 5ml sample was withdrawnwith
syringe using 0.45 mm syringe filter and the media was
replaced with the fresh media to maintain an ideal sink con-
dition. The percentage content was calculated by validated
RP-HPLCmethod and used to calculate the percentage release
on each time of dissolution profile. The cumulative percentage
of drug releasedwas plotted against time in order to obtain the
release profile [14].
The column used for separation was octadecyl silane
(C18) with length 250 mm and internal diameter 4.6 mm(Phenomenex). Mobile phase used for analysis was composed
of acetonitrile, methanol and water in the ratio of 60:20:20 (v/
v), with pH adjusted to 2.8 using orthophosphoric acid, with
flow rate of 0.5 ml/min. Sample of 20 ml was injectedmanually
and peaks were monitored at 277 nm.
To study themechanismofdrug release from theoptimized
formulation of matrix tablets, in vitro release profile were
plotted and correlated with various kinetic models like zero
order (i.e. cumulative amount of drug released vs time), first
order (log cumulative percentage of drug remaining vs time),
Higuchi model (cumulative percentage of drug released vs
square root of time) KorsmeyerePeppas (log cumulative per-
centageofdrug releasedvs log time) andHixsoneCrowell (cube
root of concentration of drug remaining vs time) equations.
2.2.4.2. In vivo studies. Tablets prepared from graft co-
polymers (F3 and F4) with acceptable physical characteristics
and optimum drug release behavior, were chosen for the in-
vivo study. Pharmacokinetic parameters of graft copolymer
formulations were compared against tablets prepared by
native starch (F1), HPMC K 100M (F5) and commercial sus-
tained release tablets (Asthalin SA-8 mg).
Male albino rabbits weighing 2.5e3.0 kg were randomly
selected for the bioavailability studies. The animals were
divided into five groups and each group comprised of six
rabbits. Each group received one of the tested formulas
namely F1, F3, F4, F5 and Asthalin SA-8 mg. The animals were
fasted over night (before administering tablets) and during the
course of experiment, animals under trial had free access to
water. Tablets were kept behind the tongue to avoid its
destruction due to biting followed by sufficient amount of
water for easy swallowing. Blood samples (about 1 ml from
each animal) were collected from orbital sinus, before dosing
(zero time) and afterwards at different intervals post dosing
viz. at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16,18, 20, 22, and 24 h. Samples
were collected in microcentrifuge tubes containing 50 ml of
10% w/w disodium EDTA as an anticoagulant. The collected
samples were immediately centrifuged at 10000 rpm for
10 min and plasma was separated and stored at 20 C until
analysis.
A high performance liquid chromatography system of
Adept series CECIL CE 4201 with UV/Visible detector was used
for analysis. The data was recorded by using the software
“power stream”. The column used for separation was octadecyl
silane (C18) with length 250 mm, internal diameter 4.6 mm
(Phenomenex) and particle size 5 m. Chloramphenicol was
used as an internal standard. In 0.5 ml of plasma sample, 20 ml
of internal standard (100 mg/ml) was added, drug was extrac-
ted from plasma using 5 ml methanol. Mobile phase used for
analysis was composed of acetonitrile, methanol and water in
the ratio of 60:20:20 (v/v), with pH adjusted to 2.8 using
orthophosphoric acid, with flow rate of 0.5 ml/min. Sample of
20 ml was injected manually and peaks were monitored at
277 nm. Quantification of salbutamol sulphate was obtained
by plotting SS to the internal standard peak area ratio as a
function of its concentration.
2.2.5. Assay method validation
The developed method was validated following bioanalytical
guidelines [15]. Bioanalytical method validation required the
Table 2 e Angle of repose as an indicator of powder flow
property (All values are expressed as mean ± SD, n ¼ 3).
Formulation code Angle of repose Type of flow
F1 32.34 ± 0.11 Passable
F2 30.41 ± 0.23 Passable
F3 25.73 ± 0.17 Good
F4 23.45 ± 0.19 Good
F5 19.11 ± 0.20 Excellent
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recovery and precision respectively.
2.2.6. In-vivo data analysis
The plasma kinetic data were assessed with Kinetica® soft-
ware (version 5). The maximum SS concentration in serum
(Cmax) and corresponding peak time (tmax) were determined by
the inspection of the individual serum drug concen-
trationetime profiles. The elimination rate constants (Ke)
were obtained from least square fitted terminal log-linear
portion of the serum concentrationetime profile. The elimi-
nation half life (t1/2) was calculated as 0.693/Ke. The area
under the plasma concentrationetime curve [AUC] 024 was
determined by linear trapezoidal rule until last measurement
point.
2.2.7. In-vitro-in-vivo correlation (IVIVC) study
In order to establish a level A IVIVC, the WagnereNelson
method [16,17] was used to calculate the percentage of the
drug absorbed:
FðtÞ ¼ CðtÞ þ keAUCð0tÞ
where F(t) is the amount absorbed. The fraction absorbed is
determined by dividing the amount absorbed at any time by
the plateau value, keAUCð0∞Þ:
Fraction absorbed

Fa

¼ CðtÞ þ keAUCð0tÞ
keAUCð0∞Þ
In-vitro fraction of drug released at each time points was
subjected to Weibul model fit options in IVIVC tool kit of
WinNonlin v 5.3. Level A IVIVC was developed by drawing a
plot between the percentage drug absorbed (along y-axis) of a
formulation and its percentage drug dissolved (along x-axis)
followed by the regression analysis of each curve to evaluate
the strength of correlation determining whether the curve is
linear or non-linear [18,19]. The closer the value of determi-
nation coefficient to 1, the stronger is the correlation and
linear is the curve. The correlation coefficient, prediction error
of Cmax and AUC were calculated to validate the predictability
of IVIVC.Table 3e Physical properties of formulated salbutamolmatrix t
retardants. (All values are expressed as mean ± SD, n ¼ 3).
Formulation code Weight deviation (mg) Hardness (kg/c
F1 204 ± 2.1 3.27 ± 0.57
F2 206 ± 2.1 3.35 ± 0.87
F3 203 ± 1.9 3.49 ± 0.92
F4 205 ± 2.3 4.01 ± 0.53
F5 204 ± 2.7 3.76 ± 0.732.2.8. Statistical analysis
Data were subjected to analysis of variance (ANOVA) (Graph
Pad Instat software v 3.06, CA, USA). Significant differences
between formulations were analyzed using student newmann
keulsmultiple comparison test and obtained p values of <0.05
were considered to be statistically significant.3. Results and discussion
3.1. Flow property (angle of repose)
Prior to compression, blends (F1eF5) were evaluated for their
flow property. From the values of angle of repose, it is evident
that blends having graft copolymers showed better flow
properties than that of blends having acetylated starch and
native starch (Table 2). For formulation containing maize
starch (F1) and acetylated starch (F2), flow propertywas falling
in the passable range, in which values of angle of repose were
found to be 32.34 ± 0.11 and 30.41 ± 0.23 respectively (31e34
is said to be a passable range). While formulation with
St-g-PMMA (F3) and Ast-g-PMMA (F4) had good flow property,
wherein values of angle of repose were 25.73 ± 0.17 and
23.45± 0.19 respectively. Hypromellose (F5) containing blend
depicted excellent flow property (wherein angle of repose was
19.11± 0.20).
3.2. Standard physical test of tablets
Formulations of salbutamol sulphate (F1eF5) with mentioned
array of excipients had thickness ranging from 3.19 to
3.41 mm (Table 3). Drug content was found to be uniform
among different batches of the tablets andwas found between
100.98 and 104.21%. Hardness and percentage friability of the
tablets of all the batches were found amid 3.27e4.01 kg/cm2
and 0.53e0.84 %, respectively. Tablets with all the aforesaid
compositions passed USP criteria for friability (<1.00% w/w).
Outcome from friability assessment revealed good mechani-
cal strength of the tablets. The percentage of weight variation
of individual tablet to that of averageweight was foundwithin
±5% w/w, which fits in USP criteria for weight variation.
3.3. In-vitro release study
The in-vitro release profile of salbutamol sulphate matrix
tablets in SGF followed by SIF is shown in Fig. 1. Study was
conducted for the period of 14 h and a higher percentage of
drug release was observed for matrices containing native
starch (F1) compared with the ones having acetylated starch
(F2) and graft copolymers (F3 & F4). The release of drug wasablets using graft copolymers and HPMCK 100M as release
m2) Friability (%) Thickness, mm % Drug content
0.75 ± 0.24 3.24 ± 0.22 102.47 ± 2.6
0.53 ± 0.21 3.26 ± 0.52 100.98 ± 2.3
0.69 ± 0.17 3.37 ± 0.47 101.57 ± 2.8
0.77 ± 0.29 3.19 ± 0.38 104.21 ± 2.9
0.84 ± 0.19 3.41 ± 0.29 103.61 ± 3.1
Fig. 1 e Release profiles of model drug salbutamol sulphate
(SS) in SGF followed by SIF at 37 C, with starch (F1),
acetylated starch (F2), St-g-PMMA (F3), Ast-g-PMMA (F4),
HPMC K 100 M (F5) as carriers, and commercial sustained
release tablets (Asthalin SA-8 mg). Vertical bars represents
mean ± SD (n ¼ 3).
Fig. 2 e (A). Chromatogram for placebo (Specificity study).
(B). HPLC chromatograms of salbutamol sulphate in graft
copolymer matrix.
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(F3 & F4) and up to 6 h for matrices containing acetylated
starch (F2) whereas in case of starch >85% drug was released
within 2 h. Significant retardation in drug release behavior of
graft copolymer matrices could be attributed by a better
swelling property of the polymers, while a fast drug release
behavior of starch was attributed by the burst release ten-
dency of starch causing tablets to break after immersing in
dissolution media.
In SGF media, a remarkable decrement in drug release was
observed in graft copolymer matrices, when St-g-PMMA was
used as a carrier then 10.7% of the drug was released in initial
2 h, 13.8% of the drug was release in case of Ast-g-PMMA
whereas tablets containing HPMC K 100M and commercial
sustained release tablets (Asthalin SA-8 mg) showed % drug
release 23.6% & 30.2% respectively. Comparison of drug
release pattern of graft copolymers matrices (F3 and F4) with
HPMC K 100M containing tablets & commercial sustained
release tablets (Asthalin SA-8 mg) in SIF media revealed that
formulation F3 and F4 released upto 74.4% and 82.5% of the
drug in successive 12 hwhile at same time point HPMCK 100M
tablets released 76.8% and Asthalin SA-8 mg released 87.8% of
the drug. Retardation in drug release rate for graft copolymer
formulations (F3 & F4) was almost equivalent to that of
commercially used controlled release polymer i.e. HPMC K
100M and commercially available sustained release tablets
(Asthalin SA-8 mg). Thus it can be inferred based on release
profile of graft copolymer and commercially available
formulation that graft copolymer has a potential application
as a control release excipient in modified drug delivery.
3.4. Analytical method validation
The developedmethodwas validated following ICH guidelines
[20]. The in-vitro release study was validated to salbutamol
tablets through the determination of specificity, linearity,
precision and accuracy.3.4.1. Specificity
The specificity of the in-vitro release test was evaluated
through the analysis of placebo tablets (Fig. 2A). The speci-
ficity test by HPLC demonstrated that the excipients from
tablets do not interfere in the drug peak because retention
times of placebo (3.02min) and salbutamol sulphate (5.22min)
are quite different (Fig. 2B).
3.4.2. Linearity
Linearity of the method was evaluated at five concentration
levels ranging from 2 to 10 mg/ml (y ¼ 30874x  6522) with
correlation coefficient of 0.9968.
3.4.3. Precision
The precision of the in-vitro release study were evaluated by
analyzing intra-day precision and inter-day precision. The %
RSD for intra-day precision is 1.68% and inter-day precision is
0.98%. According to ICH norms, in all condition %RSD was <2
which shows method is precise.
3.4.4. Accuracy
Recovery studies were performed to validate the accuracy of
developed method. To the preanalysed sample solution, a
definite concentration of standard drug was added and then
its recovery was analyzed. The method was found to be ac-
curate with % recovery of 98.42e101.53%.
Table 4 e Comparative release kinetics parameter of all the batches of controlled release tablets.
Formulation code Release kinetic parameters
Zero order First order Higuchi HixoneCrowell KorsemeyerePeppas
r2 K0 r
2 K1 r
2 KH r
2 KHC r
2 nP
F1 0.324 3.18 0.858 0.109 0.576 17.92 0.649 0.166 0.788 0.33
F2 0.646 5.25 0.979 0.129 0.864 25.67 0.889 0.261 0.83 0.38
F3 0.949 5.71 0.991 0.061 0.995 24.68 0.981 0.156 0.929 0.63
F4 0.951 5.42 0.989 0.051 0.991 23.38 0.987 0.138 0.988 0.67
F5 0.937 5.36 0.993 0.052 0.996 23.33 0.988 0.14 0.992 0.6
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The drug release mechanismwas determined by fitting the in-
vitro release profile in various release kinetic models and the
values of release exponent (nP), kinetic constant (K) and
regression coefficient are shown in Table 4. Zero order, first
order, Higuchi, HixoneCrowell and KorsmeyerePeppas are
the major models to identify the drug release from sustained
release formulations and criteria of selecting the most
appropriate model was based on the its goodness of fitting.
Starch and acetylated starch tablets (F1 &F2) showed a first
order release, with regression value of 0.858 and 0.979
respectively. In-vitro release profile of graft copolymers matrix
formulations (F3 & F4) and HPMC K 100M containing tablets
(F5) are best expressed by the Higuchi model, as the plots
showed high linearity with regression value of 0.995, 0.991,
and 0.996 followed by first order kinetics with regression value
of 0.991, 0.989, and 0.993 respectively. Two factors, however,
diminish the applicability of Higuchi's equation to matrix
systems. This model fails to explain the influence of swelling
of the matrix upon hydration and gradual erosion of the ma-
trix. Therefore, the in-vitro release data were also fitted to the
well-known exponential KorsmeyerePeppas equation and
value of release exponent (nP) explains the releasemechanism
of the drug from the tablets. The observed ‘nP’ values for
release profiles of formulation F3, F4 and F5 were fall in be-
tween 0.50 and 0.89 indicated anomalous release behavior
coupled with diffusion and erosion. The release exponents for
formulation F1 and F2 are less than 0.5 indicating quasi fickian
diffusion mechanism of drug release.
3.6. In-vivo study
The results of the plasma drug concentration at different time
intervals, after administration of formulation F1, F3, F4, F5 andTable 5 e Pharmacokinetic parameters of formulated (F1, F3, F
sulphate in rabbits (All values are expressed as mean ± SD, n
Pharmacokinetic parameters F1 F3
Cmax (ng/ml) 924.1 ± 10.1 578.9 ± 9.1
tmax (h) 1.5 ± 0.23 6.0 ± 1.3
[AUC] 024 (ng-h/ml) 5261.19 ± 5.1 6460.12 ± 8.3
Ke (h1) 0.127 ± 0.017 0.057 ± 0.0
t1/2 (h) 5.45 ± 0.59 12.15 ± 0.9
a Significantly different from starch matrix tablets (P < 0.05).Asthalin SA-8 mg tablet containing 8 mg of salbutamol sul-
phate to rabbits, are presented in Table 5. SS was detected and
quantified in plasma by using HPLCmethod andmean plasma
concentration curve of formulated tablets and commercial
tablets were plotted as depicted in Fig. 3.
Graft copolymer matrices (F3 & F4) and starch matrix (F1)
showed significantly different (P < 0.05) Cmax values of about
578.9, 546.7 and 924.1 ng/ml, respectively. Decrement of Cmax
value in case of controlled release tablets indicated and
justified sustained and prolonged release potential of graft
copolymer. Observed mean plasma [AUC] 024 values for F3
(6460.12 ng h/ml) and F4 (6679.48 ng h/ml) was significantly
(P < 0.05) higher than F1 (5261.19 ng h/ml) which indicated
improvement in relative bioavailability of graft copolymer
matrices. The tmax value of graft copolymer matrices F3 (6 h)
and F4 (7.5 h) was significantly (P < 0.05) higher than starch
matrix F1 (1.5 h), which indicates the slow absorption rate in
graft copolymer tablets due to extended release effect of
hydrophobic polymer matrix. When elimination rate con-
stants (Ke) for above mentioned formulations were
compared, it was found that formulation F1 has Ke value was
0.127, this Ke value significantly went down in F3 (Ke ¼ 0.057)
and F4 (Ke ¼ 0.053), indicating slow elimination rate of the
drug from body in graft copolymer formulations. The elimi-
nation half life (t½) of the F3 (12.15 h) and F4 (13.07 h) was
more than F1 (5.45 h), which confirmed prolonged availabil-
ity of SS in body. However there was no significant difference
in the pharmacokinetic parameters (tmax, Cmax, AUC, Ke, and
t1/2) for graft copolymers matrices, HPMC K100M matrix
tablets and commercial tablets. Results revealed that the
graft copolymer matrices provided comparable sustained
and prolonged effect to that of HPMC K 100M matrix tablets
and Asthalin SA-8 mg (commercial tablets), so graft co-
polymers can be used as potential excipients in controlled
drug delivery system.4 & F5) and marketed tablets (Asthalin SA) of salbutamol
¼ 3).
F4 F5 Asthalin SA
a 546.7 ± 8.9a 598.1 ± 10.7a 601.9 ± 6.3a
a 7.5 ± 1.2a 6.2 ± 1.1a 7.1 ± 0.75a
6679.48 ± 7.5 6276.34 ± 6.8 6592.28 ± 5.8
11a 0.053 ± 0.011a 0.049 ± 0.012a 0.059 ± 0.014a
1a 13.07 ± 1.21a 14.14 ± 1.09a 14.43 ± 0.87a
Fig. 3 e Comparative in-vivo pharmacokinetic study of
tablets having starch matrix (F1), graft copolymer matrices
(F3 and F4), HPMC K 100 M matrix (F5) and Asthalin SA.
Vertical bars represents mean ± SD (n ¼ 3).
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3.7.1. Selectivity
The chromatogram of salbutamol sulphate extracted from
plasma is shown in Fig. 4. With the chromatogram it is clear
that retention times of plasma (2.03 min) and salbutamol
sulphate (5.21 min) are quite different means plasma com-
ponents are not showing interference with the drug elution.
3.7.2. Limit of detection (LOD) and Limit of quantification
(LOQ)
LOD and LOQ for salbutamol sulphate were 33.97 ng/ml and
101.91 ng/ml, respectively.
3.7.3. Linearity
Standard calibration curve in rabbit plasma was found to be
linear at concentrations ranging from 100 to 1200 ng/ml
(Y ¼ 0.0318x þ 1.4027) with correlation coefficient of 0.9968.Fig. 4 e HPLC chromatogram of salbutamol sulphate
extracted from plasma.3.7.4. Accuracy
Recovery studies were performed to validate the accuracy of
developedmethod. To preanalysed sample solution, a definite
concentration of standard drug was added and then its re-
covery was analyzed. The method was found to be accurate if
% recovery is 100 ± 15% and % CV is <15%. The % recovery of
drug in plasma found in the range of 89.59e92.41% and coef-
ficient of variation was 2.21e3.81. Since the % recovery and %
CV is within the range, it shows accuracy of method.
3.7.5. Precision
Precision of the method was assessed by intra-day and inter-
day analysis of six replicates for each concentration at 3
different concentration levels (100, 600, and 1200 ng/ml,
respectively). The coefficient of variation (CV) at each con-
centration level was expressed as precision. The method
proved to be precise because the % CV for is not more than
5.61% at three different concentration levels.3.8. In-vitro-in-vivo correlation
In-vitro-in-vivo correlation was established by plotting the
graph of fraction absorbed in-vivo against fraction dissolved
in-vitro. In this study, Fa and Fd data of graft copolymerFig. 5 e Plot of the fraction absorbed in-vivo vs. fraction
dissolved in-vitro for graft copolymer formulations F3 & F4
respectively.
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(R2 > 0.97) was observed between fraction dissolved in-vitro
and fraction absorbed in-vivo shown in Fig. 5. The prediction
error of the Cmax and AUC of the correlation were found to be
9.62% and 12.02%. The low prediction error indicates the
reliability of model towards carrying out predictions; hence it
can be selected as a bio relevant tool to screen the best
formulation and used for waiver approval in future.4. Conclusion
Release characteristics of salbutamol sulphate was evaluated
and assessed using graft copolymer as a carrier matrix and
was compared with HPMC K100M containing controlled
release matrix system and marketed formulation (Asthalin
SA-8 mg). It was revealed that the graft copolymerization
improves the flow property of native starch and modified
starch. Matrix tablets prepared employing graft copolymers
imparted slow release profile of up to 14 h, similar was in case
of HPMC K100M matrix formulation.
Statistical model and kinetic data revealed that in graft
copolymer based matrices; drug release was governed by
diffusion and erosion mechanism. The in-vitro release profiles
of salbutamol sulphate starch matrix tablets showed >70%
drug release within 1 h whereas in graft copolymer matrix
tablets same amount of drug was released upto 9 h. This re-
flects the potential of graft copolymers to sustain the drug
release and the results are well supported by in-vivo phar-
macokinetic studies. Pharmacokinetic parameter i.e. tmax
(1.5 ± 0.23 h) values of the starch matrix tablets clearly in-
dicates the ability of the formulation to release the drug
immediately upon reaching the GIT which is due to the hy-
drophilic nature and high solubility of starch. The dramatic
shift in tmax of the graft copolymermatrix tablets [F3 (6.0 ± 1.3)
& F4 (7.5 ± 1.2) h] w.r.t starch matrix tablets (1.5 ± 0.23 h) are
indicative of the graft copolymer carrier to control the release
of the drug even under the gastrointestinal environment.
Whereas pharmacokinetic parameters (tmax, Cmax, AUC, Ke,
and t1/2) of graft copolymers matrices (F3 & F4), HPMC K 100M
matrix tablets (F5) and marketed tablets are comparable,
indicating that graft copolymers might be a promising vehicle
for sustained release preparations in oral therapy. A well in-
vitro-in-vivo correlation was observed for graft copolymer
formulations, which indicates their suitability for the waiver
approval in future.
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